Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; TIKHE, J et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2819-2834, issn 0022-2623Article

Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agentsBORCH, R. F; JIWEN LIU; SCHMIDT, J. P et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 11, pp 2258-2265, issn 0022-2623Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P₁ lactam moieties as L-glutamine replacementsDRAGOVICH, P. S; PRINS, T. J; BURKE, B. J et al.Journal of medicinal chemistry (Print). 1999, Vol 42, Num 7, pp 1213-1224, issn 0022-2623Article

Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acidsDRAGOVICH, P. S; WEBBER, S. E; BROWN, E. L et al.Bioorganic & medicinal chemistry letters (Print). 1999, Vol 9, Num 15, pp 2189-2194, issn 0960-894XArticle

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; LITTLEFIELD, E. S et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2806-2818, issn 0022-2623Article